Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Abstract As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodrigo Jácome, José Alberto Campillo-Balderas, Samuel Ponce de León, Arturo Becerra, Antonio Lazcano
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/27f5e92cc72e48598ae0a79c08b15f67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:27f5e92cc72e48598ae0a79c08b15f67
record_format	dspace
spelling	oai:doaj.org-article:27f5e92cc72e48598ae0a79c08b15f672021-12-02T17:52:13ZSofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic10.1038/s41598-020-66440-92045-2322https://doaj.org/article/27f5e92cc72e48598ae0a79c08b15f672020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-66440-9https://doaj.org/toc/2045-2322Abstract As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.Rodrigo JácomeJosé Alberto Campillo-BalderasSamuel Ponce de LeónArturo BecerraAntonio LazcanoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-5 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rodrigo Jácome José Alberto Campillo-Balderas Samuel Ponce de León Arturo Becerra Antonio Lazcano Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
description	Abstract As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
format	article
author	Rodrigo Jácome José Alberto Campillo-Balderas Samuel Ponce de León Arturo Becerra Antonio Lazcano
author_facet	Rodrigo Jácome José Alberto Campillo-Balderas Samuel Ponce de León Arturo Becerra Antonio Lazcano
author_sort	Rodrigo Jácome
title	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_short	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_full	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_fullStr	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_full_unstemmed	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_sort	sofosbuvir as a potential alternative to treat the sars-cov-2 epidemic
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/27f5e92cc72e48598ae0a79c08b15f67
work_keys_str_mv	AT rodrigojacome sofosbuvirasapotentialalternativetotreatthesarscov2epidemic AT josealbertocampillobalderas sofosbuvirasapotentialalternativetotreatthesarscov2epidemic AT samuelponcedeleon sofosbuvirasapotentialalternativetotreatthesarscov2epidemic AT arturobecerra sofosbuvirasapotentialalternativetotreatthesarscov2epidemic AT antoniolazcano sofosbuvirasapotentialalternativetotreatthesarscov2epidemic
_version_	1718379216273145856

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Ejemplares similares